The obtained data reveal novel mechanisms of FGF23+ PMT development involving MCs and may be used in translational medicine by supporting the development of new algorithms for personalized therapies as alternatives to surgical treatment when tumour removal is not feasible [76]. This evidence concerns the gene FGF23 and neoplasm.